28 June 2017 - Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours.

The Institute has now published final guidance recommending both drugs for ‘routine’ NHS commissioning when NETs of pancreatic origin cannot be operated on and have progressed.

Afinitor (everolimus) can also be considered an option for patients with neuroendocrine tumours of a gastro-intestinal or lung origin when the disease has progressed.

Read Pharma Times article